Lilly invested $50B in new US factories
Eli Lilly has invested approximately $50 billion in new manufacturing facilities in the United States to address drug supply shortages.
Snapshot · The Prof G Pod with Scott Galloway
Why People Are Losing Faith in Healthcare
Explore episode
Jun 4, 2026
Where this was said
Pricing, Access, and the LillyDirect Model
At 16:50 · chapter starts 16:10
The pricing question is the sharpest edge of the conversation. Galloway frames it as a contradiction: Lilly has a fiduciary duty to shareholders to maintain pricing power, but the people who need these drugs most — lower-income, obese Americans — are least likely to afford them. Ricks reframes the economics: unlike most specialty drugs where demand is inelastic, GLP-1 demand is highly elastic — drop the price and volume surges. So lowering the price actually serves shareholders, not just patients. He details LillyDirect, a direct-to-consumer channel that bypasses pharmacy benefit managers and lets individuals buy at institutional prices — Zepbound is now $399/month, down 60% since launch. The new oral drug Foundeo starts at $159. Ricks then describes the Mississippi Medicaid deal — a state where 78–79% of adults are obese and Medicaid enrollment is the nation's highest — as a proof point of what systemic change can look like. And starting July 1, all 70 million Medicare seniors can access Lilly's obesity drug for $50/month. The final challenge: trust. Because pharma has historically been extractive on pricing, Ricks admits there's a genuine trust gap to overcome.
Zepbound list price fell 60% to $399
The direct-purchase price for Zepbound has dropped 60% since launch to $399/month through LillyDirect, with the oral Foundeo starting at $159.
Mississippi: 78–79% adult obesity rate
Mississippi has one of the highest adult obesity rates in the US at 78–79%, the highest Medicaid enrollment, and is one of the poorest states — but Lilly just struck a deal to supply its drugs through their Medicaid program.
Medicare's $50/Month Moment: 70 Million Seniors Get Access July 1
Starting July 1, every Medicare senior in America can buy Lilly's obesity medication for $50 out-of-pocket per month. This single policy shift could extend GLP-1 access to 70 million people, and represents a meaningful inflection point for both public health and Lilly's volume strategy.
Medicare seniors: $50/month starting July 1
Starting July 1, every Medicare senior in America can access Lilly's obesity medication for just $50 out-of-pocket per month, potentially impacting 70 million people.
Similar snapshots
80% of time above the fold
Focus 80% of your landing page design effort on the hero section — the first thing visitors see when they open the website.
Hero section carries full message
The hero section must convey the product's complete value proposition on its own, so visitors instantly understand what it is.
First couple of seconds matter most
Visitors decide whether to stay or leave within just a few seconds, so immediate clarity is essential on any landing page.
Pain-point headline drives conversion
Highlighting time savings, money savings, or a painful problem solved in the headline and subheading is the core conversion lever.
Big CTA essential above the fold
A prominent call-to-action must accompany the headline and subheading in the hero section to capture visitor intent immediately.
$25K/month revenue
Avnish's solopreneur business reached $25,000 per month in revenue using a community-driven, zero-ad-spend marketing strategy.
15 months to $25K/month
Avnish scaled his business from zero to $25K/month in just 15 months using a single core marketing strategy.
Zero marketing spend
Avnish acquired thousands of users without spending any money on marketing, relying entirely on Reddit and Facebook groups.
Single thousands to tens of thousands of users
One specific Reddit or Facebook post was responsible for taking Avnish's user base from single thousands to tens of thousands.
